Literature DB >> 26423389

Time course of postprandial hepatic phosphorus metabolites in lean, obese, and type 2 diabetes patients.

Maria Fritsch1, Chrysi Koliaki2, Roshan Livingstone3, Esther Phielix3, Alessandra Bierwagen4, Markus Meisinger3, Tomas Jelenik4, Klaus Strassburger5, Stefanie Zimmermann4, Katharina Brockmann4, Christina Wolff4, Jong-Hee Hwang4, Julia Szendroedi2, Michael Roden6.   

Abstract

BACKGROUND: Impaired energy metabolism is a possible mechanism that contributes to insulin resistance and ectopic fat storage.
OBJECTIVE: We examined whether meal ingestion differently affects hepatic phosphorus metabolites in insulin-sensitive and insulin-resistant humans.
DESIGN: Young, lean, insulin-sensitive humans (CONs) [mean ± SD body mass index (BMI; in kg/m(2)): 23.2 ± 1.5]; insulin-resistant, glucose-tolerant, obese humans (OBEs) (BMI: 34.3 ± 1.7); and type 2 diabetes patients (T2Ds) (BMI: 32.0 ± 2.4) were studied (n = 10/group). T2Ds (61 ± 7 y old) were older (P < 0.001) than were OBEs (31 ± 7 y old) and CONs (28 ± 3 y old). We quantified hepatic γATP, inorganic phosphate (Pi), and the fat content [hepatocellular lipids (HCLs)] with the use of (31)P/(1)H magnetic resonance spectroscopy before and at 160 and 240 min after a high-caloric mixed meal. In a subset of volunteers, we measured the skeletal muscle oxidative capacity with the use of high-resolution respirometry. Whole-body insulin sensitivity (M value) was assessed with the use of hyperinsulinemic-euglycemic clamps.
RESULTS: OBEs and T2Ds were similarly insulin resistant (M value: 3.5 ± 1.4 and 1.9 ± 2.5 mg · kg(-1) · min(-1), respectively; P = 0.9) and had 12-fold (P = 0.01) and 17-fold (P = 0.002) higher HCLs, respectively, than those of lean persons. Despite comparable fasting hepatic γATP concentrations, the maximum postprandial increase of γATP was 6-fold higher in OBEs (0.7 ± 0.2 mmol/L; P = 0.03) but only tended to be higher in T2Ds (0.6 ± 0.2 mmol/L; P = 0.09) than in CONs (0.1 ± 0.1 mmol/L). However, in the fasted state, muscle complex I activity was 53% lower (P = 0.01) in T2Ds but not in OBEs (P = 0.15) than in CONs.
CONCLUSIONS: Young, obese, nondiabetic humans exhibit augmented postprandial hepatic energy metabolism, whereas elderly T2Ds have impaired fasting muscle energy metabolism. These findings support the concept of a differential and tissue-specific regulation of energy metabolism, which can occur independently of insulin resistance. This trial was registered at clinicaltrials.gov as NCT01229059.
© 2015 American Society for Nutrition.

Entities:  

Keywords:  hepatic steatosis; mitochondrial function; mixed-meal test; phosphorus magnetic resonance spectroscopy; type 2 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26423389     DOI: 10.3945/ajcn.115.107599

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  14 in total

1.  Aerobic capacity and hepatic mitochondrial lipid oxidation alters susceptibility for chronic high-fat diet-induced hepatic steatosis.

Authors:  E Matthew Morris; Grace M E Meers; Lauren G Koch; Steven L Britton; Justin A Fletcher; Xiaorong Fu; Kartik Shankar; Shawn C Burgess; Jamal A Ibdah; R Scott Rector; John P Thyfault
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-09-06       Impact factor: 4.310

Review 2.  The Role of Mitochondrial Adaptation and Metabolic Flexibility in the Pathophysiology of Obesity and Insulin Resistance: an Updated Overview.

Authors:  Dimitrios Tsilingiris; Evangelia Tzeravini; Chrysi Koliaki; Maria Dalamaga; Alexander Kokkinos
Journal:  Curr Obes Rep       Date:  2021-04-10

3.  Acute dietary fat intake initiates alterations in energy metabolism and insulin resistance.

Authors:  Elisa Álvarez Hernández; Sabine Kahl; Anett Seelig; Paul Begovatz; Martin Irmler; Yuliya Kupriyanova; Bettina Nowotny; Peter Nowotny; Christian Herder; Cristina Barosa; Filipa Carvalho; Jan Rozman; Susanne Neschen; John G Jones; Johannes Beckers; Martin Hrabě de Angelis; Michael Roden
Journal:  J Clin Invest       Date:  2017-01-23       Impact factor: 14.808

Review 4.  NAFLD and diabetes mellitus.

Authors:  Herbert Tilg; Alexander R Moschen; Michael Roden
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-10-12       Impact factor: 46.802

Review 5.  Altered mitochondrial function in insulin-deficient and insulin-resistant states.

Authors:  Gregory N Ruegsegger; Ana L Creo; Tiffany M Cortes; Surendra Dasari; K Sreekumaran Nair
Journal:  J Clin Invest       Date:  2018-08-31       Impact factor: 14.808

6.  Mechanisms of Insulin Resistance in Primary and Secondary Nonalcoholic Fatty Liver.

Authors:  Tomas Jelenik; Kirti Kaul; Gilles Séquaris; Ulrich Flögel; Esther Phielix; Jörg Kotzka; Birgit Knebel; Pia Fahlbusch; Tina Hörbelt; Stefan Lehr; Anna Lena Reinbeck; Dirk Müller-Wieland; Irene Esposito; Gerald I Shulman; Julia Szendroedi; Michael Roden
Journal:  Diabetes       Date:  2017-05-10       Impact factor: 9.461

7.  High-resolution respirometry in human endomyocardial biopsies shows reduced ventricular oxidative capacity related to heart failure.

Authors:  Daniel Scheiber; Tomas Jelenik; Elric Zweck; Patrick Horn; Heinz-Peter Schultheiss; Dirk Lassner; Udo Boeken; Diyar Saeed; Malte Kelm; Michael Roden; Ralf Westenfeld; Julia Szendroedi
Journal:  Exp Mol Med       Date:  2019-02-14       Impact factor: 8.718

8.  Dynamic changes of muscle insulin sensitivity after metabolic surgery.

Authors:  Sofiya Gancheva; Meriem Ouni; Annette Schürmann; Michael Roden; Tomas Jelenik; Chrysi Koliaki; Julia Szendroedi; Frederico G S Toledo; Daniel F Markgraf; Dominik H Pesta; Lucia Mastrototaro; Elisabetta De Filippo; Christian Herder; Markus Jähnert; Jürgen Weiss; Klaus Strassburger; Matthias Schlensak
Journal:  Nat Commun       Date:  2019-09-13       Impact factor: 14.919

Review 9.  Mitochondrial Dysfunction in the Transition from NASH to HCC.

Authors:  Mélissa Léveillé; Jennifer L Estall
Journal:  Metabolites       Date:  2019-10-16

10.  miR‑146a improves hepatic lipid and glucose metabolism by targeting MED1.

Authors:  Kun Li; Bao Zhao; Diandian Wei; Wenrui Wang; Yixuan Cui; Lisheng Qian; Guodong Liu
Journal:  Int J Mol Med       Date:  2019-12-27       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.